The trial will test the safety and efficacy of intra-articular injections of autologous human adipose-derived mesenchymal progenitor cells (haMPC) to reduce inflammation and regenerate damaged joint tissues.
Cellular Biomedicine president Dr. William Cao said the patient enrollment achievement in the clinical trial is a milestone for CBMG.
"We anticipate that enrollment will continue to move quickly and the study is on schedule to complete its Phase I clinical trial," Cao added.
The trial, registered with the US National Institutes of Health (NIH), is conducted at Shanghai Renji Hospital in China.